Navigation Links
BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
Date:10/27/2008

e adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commi
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Pittcon marketing department is pleased to announce ... app, Pittcon 2015 . The ... for iOS and Android devices and the Kindle Fire, ... after the event. It acts as an all-inclusive real-time ... Conferee Networking sessions and short courses. , The Pittcon ...
(Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
(Date:11/26/2014)... , Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, today ... the Piper Jaffray  26 th Annual Healthcare Conference on ... held at The New York Palace in New ... material information concerning the Company, its operations, strategies and prospects ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... First Milestone, NEW YORK, May 13 NeoStem, ... collection, processing and long-term,storage of adult stem cells for ... secured for a new stem cell collection center in ... MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: "Securing ...
... call scheduled today at 8:00 a.m. Pacific Time, ... ) today announced its financial results for the first ... 2008, the Company posted,total revenues of $17.0 million and ... of revenue earned in the quarter that was,attributable to ...
... responsible for coordinating nanotechnology research and regulations across the ... University to craft a white paper that will lay ... risks associated with nanotechnology to the media and the ... been negotiating this project for nearly 18 months. , ...
Cached Biology Technology:NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 2SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 4SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 5SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 6SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 7SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 8Federal government taps NC State experts to explain nanotech risks 2
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/7/2014)... November 6, 2014 Leading Biometric companies ... mobile security revolutionizing online transactions.  Companies in focus today are: ... (NYSE: BABA ), Google Inc. (NASDAQ: ... Inc. (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: ... and NXTDW), a biometric authentication company focused on the growing ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... Researchers from the University of North Carolina at Chapel ... million to study the many ways cocaine use during ... infants. The project,s researchers hope their findings will ... both mothers and children, and prove valuable to others ...
... Energy and Environmental Policy Research have produced a report ... are under consideration in the United States as a ... of the three-part study found that, based on an ... U.S. programs for other emissions, such a program can ...
... Cerveny arrived in coastal southeast Alaska in 1999, she ... the natural environment. She soon found, however, that women ... and making sense of the changes that were taking ... on the fly, ultimately conducting more than 200 hour-long ...
Cached Biology News:UNC, Yale partner to study effects of cocaine use on mother-infant relationships 2MIT analysis shows how cap-and-trade plans can cut greenhouse emissions 2Balance between traditional activities, tourism key to sustaining coastal Alaska communities 2
Component in MasterPure™ Purification Kits...
... (X/R) Red System consists of concentrated ... and X/R Red Buffer. The X/R ... to produce red staining that may ... , Buffer, 100 mL , Chromogen, ...
... Signets FAST RED Chromogen System ... and substrate buffer. FAST RED ... alkaline phosphatase to produce red ... The FAST ...
Mouse Cell Line Slides...
Biology Products: